BMI ups forecast for Swedish pharmaceuticals market

While Sweden boasts one of the most admirable economies in the world, its pharmaceutical market is not considered as attractive as that of most of its Western European peers. This is mostly due to the country's modest population size, under 10 million people, as its per capita spending levels are comparable to those in major European markets, notes a new report from Business Monitor International.

Risks to report forecasts are on the upside and the downside: the former in terms of higher public spending given the fast pace of economic recovery, with the latter based on pricing pressures should export economies falter, causing a Swedish economic slowdown, says BMI.

Headline expenditure projections: